利用小鼠模式探討中草藥對代謝症候群危險因子之影響

代謝症候群是一種包含肥胖、血壓偏高、血糖偏高以及血脂異常等多項危險因子綜合表現的臨床徵候，伴隨著這些危險因子的增加，罹患心血管疾病、糖尿病和高血壓的機率也相對提升。根據行政院衛生署 2011 年公佈的國人十大死因中，心臟疾病、腦血管疾病、糖尿病、腎相關疾病以及高血壓性疾病等多項與代謝症候群相關的疾病，其總死亡率遠高於排名第一的惡性腫瘤。因此，本研究利用 C57BL/6 純種品系小鼠，藉由注射Streptozocin (STZ) 並餵食高脂質飼料，建立代謝症候群小鼠模式後，再經由口服餵食三黃瀉心湯，以評估三黃瀉心湯是否可以有效改善代謝症候群之危險因子，並探討三黃瀉心湯改善代謝症候群之相關機制。實驗結果發現，小鼠注射 STZ 並餵食高脂質飼料八週後，可成功建立具有高血糖、葡萄糖不耐症、高膽固醇血症、脂肪肝以及發炎反應等多項代謝症候群危險因子之小鼠動物模式；而每天口服餵食三黃瀉心湯十一週後，結果發現，餵食三黃瀉心湯雖然無法有效改善小鼠之高血糖及高膽固醇血症，但可降低小鼠肝臟重量及肝臟內三酸甘油酯濃度，減低血漿中 E-selectin 濃度，並提升脂肪組織 PPARγ2、肝臟 PPARα、及降低肝臟 IL-6、TNF-α、IL-1β、COX-2 和 mPGES1 等發炎或調節因子的 mRNA 表現。因此，總結本研究結果，C57BL/6 純種品系小鼠注射 STZ 且餵食高脂質飼料，可成功建立具有高血糖、葡萄糖不耐症、高膽固醇血症、脂肪肝以及發炎反應等多項代謝症候群危險因子之小鼠動物模式；而口服三黃瀉心湯，雖無法有效改善小鼠高血糖及高膽固醇血脂症之徵候，但可改善脂肪肝及肝臟之脂質代謝、增加脂肪組織代謝作用，並減緩小鼠發炎反應，可作為改善發炎反應及脂質代謝之藥物。

關鍵字

代謝症候群；小鼠模式；中草藥

並列摘要

Metabolic syndrome is characterized by obesity, hypertension, hyperglycemia and dyslipidemia as well as a cluster of risk factors. Along with these risk factors rising, the probability of suffering from cardiovascular disease, diabetes and hypertension would be increased. In Taiwan, the total mortality of metabolic-syndrome-related diseases including cardiovascular diseases, cerebrovascular diseases, diabetes, kidney diseases, and hypertension-related diseases is higher than cancers. In order to establish a mouse model with the risk factors of metabolic syndrome, C57BL/6 male mice were injected with streptozocin (STZ) and fed with high-fat diet for eight weeks. After that, San-Huang-Xie- Xin-Tang (SHXT) was orally administrated daily for 11 weeks to evaluate whether the SHXT could ameliorate metabolic syndrome and to study its molecular mechanisms. The results showed that a mouse model with hyperglycemia, glucose intolerance, hypercholesterolemia, fatty liver and intensive inflammation was successfully established. Although SHXT failed to improve hyperglycemia and hyper- cholesterolemia, it reduced liver weight and triacylglyceride, and plasma E-seletctin concentration, increased the expression of adipose PPARγ2, and hepatic PPARα, decreased hepatic IL-6, TNF-α, IL-1β, COX-2 and mPGES1 mRNA. In conclusion, C57BL/6 mice injected with STZ and fed with high-fat diet for 8 weeks is a good model for evaluating the treatment for improving hyperglycemia, glucose intolerance, hypercholesterolemia, fatty liver and inflammation. Although oral admi- nistration of SHXT could not improve some of the metabolic risk factors effectively, it could modulate fatty liver, adipose and hepatic lipid metabolism, and inflammation.

並列關鍵字

Chinese herbal medicine ； Metabolic syndrome ； Mouse model

參考文獻

1. 行政院衛生署國民健康局公告修訂代謝症候群指標。2007。

2. 行政院衛生署99年度死因統計。2011。

18. Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000; 62:413.

19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complication. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consulation. Diabet Med. 1998; 15:539-553.

21. Bastard JP, Maachi M, Tran Van Nhieu J, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin EndocrinolMetab. 2002; 87:2084.

國際替代計量

利用小鼠模式探討中草藥對代謝症候群危險因子之影響

未授權

主題瀏覽